Interview with Patrik De Haes, Chief Executive Officer, ThromboGenics
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Address: Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 (0) 16 75 13 10
Web: http://thrombogenics.com/
Thrombogenics NV is a Belgium-based biopharmaceutical company focused on the discovery and development of medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has…
Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship…
Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per…
Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics…
Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA)…
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom…
Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the…
Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from…
Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future…
Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van…
See our Cookie Privacy Policy Here